Home > Insider Trading > Filing (0001209191-15-053752)

Filing Details

Accession Number:: 0001209191-15-053752
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-06-16 16:10:33
Reporting Period:: 2015-06-12

Filing Date:: 2015-06-16
Accepted Time:: 2015-06-16 16:10:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1512762	Coherus Biosciences Inc.	CHRS	Biological Products, (No Disgnostic Substances) (2836)	273615821

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1622058	J. August Troendle	C/O Coherus Biosciences, Inc. 201 Redwood Shores Parkway, Suite 200 Redwood City CA 94065		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Disposition	2015-06-12	134,167	$26.72	2,008,325	No	4	S	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Disposition	2015-06-12	1,851	$27.29	2,006,474	No	4	S	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Disposition	2015-06-15	111,606	$26.62	1,894,868	No	4	S	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Disposition	2015-06-15	2,376	$27.08	1,892,492	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	21,870	Direct
Common Stock, $0.0001 Par Value	358,428	Indirect	See Footnote

Footnotes

The transaction was executed in multiple trades in prices ranging from $26.08 to $27.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein.
The transaction was executed in multiple trades in prices ranging from $27.08 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $26.00 to $26.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $27.00 to $27.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein.